Petros Pharmaceuticals Inc (PTPI) FinancialsPTPIPetros Pharmaceuticals Inc

Petros Pharmaceuticals Inc (PTPI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical Devices, accounting for 55.9% of total sales, equivalent to $775.71K. Another important revenue stream is Prescription Medications. Understanding this composition is critical for investors evaluating how PTPI navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Petros Pharmaceuticals Inc maintains a gross margin of -26.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -240.85%, while the net margin is -1278.38%. These profitability ratios, combined with a Return on Equity (ROE) of -1164.22%, provide a clear picture of how effectively PTPI converts its operational activities into shareholder value.

In the context of the broader market, PTPI competes directly with industry leaders such as TTNP and OGEN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, PTPI's gross margin of -26.94% stands against TTNP's N/A and OGEN's N/A. Such benchmarking helps identify whether Petros Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.